Coherus Biosciences Inc. Revenue 2012–2025
Coherus Biosciences Inc. annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Coherus Biosciences Inc. revenue for the quarter ending March 31, 2026 was 12.3 M, a 61.99% increase year-over-year.
- Coherus Biosciences Inc. revenue for the twelve months ending March 31, 2026 was 41.7 M, a 55.23% decrease year-over-year.
- Coherus Biosciences Inc. annual revenue for 2025 was 42.2 M, a 59.81% increase from 2024.
- Coherus Biosciences Inc. annual revenue for 2024 was 26.4 M, a 89.74% decrease from 2023.
- Coherus Biosciences Inc. annual revenue for 2023 was 257.2 M, a 21.89% increase from 2022.
- Coherus Biosciences Inc. annual revenue for 2022 was 211.0 M.
Coherus Biosciences Inc. (CHRS) — Frequently Asked Questions
Coherus Biosciences Inc. (CHRS) is a publicly traded US company. It has a market capitalization of $159M. In fiscal 2025 it reported revenue of $42M and net income of $168M. Explore CHRS's stock price, financial statements, earnings history, margins and key ratios below.
What is Coherus Biosciences Inc.'s market cap?
Coherus Biosciences Inc. (CHRS) has a market capitalization of $159M.
What is the CHRS stock price?
CHRS trades at $1.36 (-4.23% on the day).
How much revenue does Coherus Biosciences Inc. make?
Coherus Biosciences Inc. reported revenue of $42M in fiscal 2025.
Is CHRS profitable?
In fiscal 2025, Coherus Biosciences Inc. reported net income of $168M.